Overview
Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in July 2015 on request of the sponsor.
On 8 March 2004, orphan designation (EU/3/04/191) was granted by the European Commission to Orfagen, France, for ethanol (96 per cent) (gel for injection) for the treatment of congenital venous malformations.
Key facts
Active substance |
Ethanol
|
Intended use |
Treatment of congenital venous malformations
|
Orphan designation status |
Withdrawn
|
EU designation number |
EU/3/04/191
|
Date of designation |
09/03/2004
|
Sponsor |
Orfagen
CRDPF Langlade 3 Avenue Hubert Curien - BP 13562 31035 Toulouse Cedex 1 France Tel. +33 5345 06459 Fax +33 5345 03457 E-mail: info@orfagen.com |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: